Zura Bio Q1 net loss widens as expenses rise

Zura Bio

Zura Bio

ZURA

0.00


Overview

  • U.S. biotech firm's Q1 net loss widened yr/yr as R&D and G&A expenses increased

  • Company raised $144 mln in February public offering to support pipeline advancement

  • Cash and equivalents rose to $225.6 mln, expected to fund operations through at least 2028


Outlook

  • Zura expects topline data from HS Phase 2 study in Q4 2026

  • Company expects topline data from SSc Phase 2 study in H1 2027

  • Zura says cash position expected to fund operations through at least end of 2028


Result Drivers

  • R&D SPENDING - Higher R&D expenses driven by advancement of Phase 2 tibulizumab clinical programs

  • G&A COSTS - Increased G&A expenses due to higher compensation and professional fees to support growth and clinical programs


Company press release: ID:nBw2rJZTa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$24.22 mln

Q1 Income from Operations

-$25.50 mln

Q1 Operating Expenses

$25.50 mln

Q1 Pretax Profit

-$24.22 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.